Cholinergic Receptor, Nicotinic, alpha 3 (Neuronal) (CHRNA3) (N-Term) Peptide
Quick Overview for Cholinergic Receptor, Nicotinic, alpha 3 (Neuronal) (CHRNA3) (N-Term) Peptide (ABIN974949)
Target
Origin
Source
Application
-
-
Protein Region
- N-Term
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-CHRNA3 antibody (Catalog #: ARP34964_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- CHRNA3 (Cholinergic Receptor, Nicotinic, alpha 3 (Neuronal) (CHRNA3))
-
Background
-
The CHRNA3 subunit is expressed in the soma of the majority of pyramidal cells, with the most alpha 3 immunoreactivity observed in CA2-4 and entorhinal cortex and relatively less in CA1 and subicular pyramidal cell soma.
Alias Symbols: MGC104879, LNCR2, PAOD2, NACHRA3
Protein Interaction Partner: CHRNB4,UBQLN1
Protein Size: 505 -
Molecular Weight
- 57 kDa
-
Gene ID
- 1136
-
NCBI Accession
- NM_000743, NP_000734
-
UniProt
- P32297
Target
-